Opinion|Videos|December 20, 2023

Metastatic Prostate Cancer: Background and Patient Prognosis

Author(s)Rana R. McKay, MD, Neal Shore, MD, FACS

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

Episodes in this series

EP. 1 Metastatic Prostate Cancer: Background and Patient Prognosis

EP. 1 Metastatic Prostate Cancer: Background and Patient Prognosis

EP. 2 Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP. 2 Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP. 3 Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

EP. 3 Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

EP. 4 Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP. 4 Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP. 5 Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP. 5 Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP. 6 Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP. 6 Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP. 7 Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

EP. 7 Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

September 28th, 2026

Calculating the Real Cost of False Positive Findings in Cancer Screening

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

Trending on OncLive

China's NMPA Approves Pirtobrutinib Across CLL

FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

Calculating the Real Cost of False Positive Findings in Cancer Screening

Dose Intensity Anchors JAK Inhibitor Selection as Combinations and Targeted Agents Expand Options in Myelofibrosis